Medtronic Reports Second Quarter Financial Results

Go back to Medtronic Reports Second Quarter Financial Results

Medtronic, Inc. (MDT) PT Raised to $99 at Jefferies; Q2 Eases Growth Concerns

November 22, 2017 7:45 AM EST

Jefferies raised its price target on Medtronic, Inc. (NYSE: MDT) to $99.00 (from $96.00) while maintaining a Buy rating following Q2 results.

Analyst Raj Denhoy said the results eased concerns of a slowing growth trajectory.

"Despite weather impacts, F18 guidance for +4-5% sales and... More

Medtronic, Inc. (MDT) PT Bumped to $95 at Needham & Company

November 21, 2017 3:46 PM EST

Needham & Company analyst Mike Matson bumped his price target on Medtronic, Inc. (NYSE: MDT) to $95.00 (from $94.00) while maintaining a Buy rating following Q1 results that beat the Street and reiterated guidance.

Matson notes organic revenue growth improved to 4.0% (excluding Hurricane Maria)... More

Medtronic (MDT) Tops Q2 EPS by 8c, Reiterates Guidance

November 21, 2017 6:48 AM EST

Medtronic (NYSE: MDT) reported Q2 EPS of $1.07, $0.08 better than the analyst estimate of $0.99. Revenue for the quarter came in at $7.1 billion versus the consensus estimate of $6.93 billion.

Guidance
Medtronic today reiterated its revenue and non-GAAP EPS guidance. The company's guidance is given on a comparable, constant currency basis, which accounts for the divestiture of certain businesses from its prior period Patient Monitoring & Recovery division by removing the financial impact... More